Beijing Med-Pharm Corp. said it will be added to the NASDAQ Biotechnology Index on Nov. 19.

Based in Plymouth Meeting, Pa., Beijing Med-Pharm (NASDAQ:BJGP) helps pharmaceutical and biotechnology companies get their products approved and sold in China. Its services include pre-market entry analysis, clinical trial management, product registration, market research, and pharmaceutical marketing and distribution.

David Gao, the CEO of Beijing Med-Pharm, said the company is "delighted" to be part of the index noting it "places us among some of the world's leading biotechnology companies."

The NASDAQ Biotechnology Index, like a Dow Jones Industrial Average for biotech stocks, is used to track the state of a market sector.

Companies are ranked for inclusion in the index in May and November of each year. Eligibility criteria for being part of NASDAQ's biotech index include meeting market capitalization minimums and trading volume minimums.